Policy | March 14, 2022
Draft policy on medical devices released
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
The Gujarat Biotechnology policy released last month has made radical changes to position the state as a biotechnology hub. It already has a thriving ecosystem of pharma companies and varied suppliers
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
Citizens will be able to create their ABHA (Ayushman Bharat Health Account) numbers, to which their digital health records can be linked
This policy will ensure multi-disciplinary collaboration, promote start-up culture and develop an innovation-led ecosystem at medical institutes across the country
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
AIIA partners with Startup India with the aim to identify and support innovations and start-ups working in the Ayush sector
The investment in Indian clinical technology expertise in Hyderabad comes amid the clinical trials sector's move towards decentralised trials
According to the state government, it will also provide support to special projects such as preclinical testing, genome sequencing in the private sector, private sector BSL-3 lab-vaccine development and manufacturing and testing and certification laboratories
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
Subscribe To Our Newsletter & Stay Updated
